Characterization of amphiphilic dendrimer modified PEG-PLA nanoparticles prepared by a double emulsion-solvent evaporation method

doi:10.5246/jcps.2017.07.058

Journal of Chinese Pharmaceutical Sciences ›› 2017, Vol. 26 ›› Issue (7): 521-527.DOI: 10.5246/jcps.2017.07.058

• Original articles • Previous Articles Next Articles

Characterization of amphiphilic dendrimer modified PEG-PLA nanoparticles prepared by a double emulsion-solvent evaporation method

Xin Li, Ning Pang, Ji Li, Xianrong Qi^*

Beijing Key Laboratory of Molecular Pharmaceutics and New Drug Delivery System; Department of Pharmaceutics, School of Pharmaceutical Sciences, Peking University Health Science Center, Beijing 100191, China

Received:2017-05-10 Revised:2017-05-23 Online:2017-07-28 Published:2017-06-04
Contact: Tel.: +86-010-82801584, Fax: +86-010-82801584, E-mail: qixr@bjmu.edu.cn
Supported by:
National Natural Science Foundation of China (Grant No. 81473156, 81673365, 81273454), Doctoral Foundation of the Ministry of Education (Grant No. 20130001110055), National Key Basic Research Program (Grant No. 2013CB932501).

Abstract

Abstract:

Drug delivery by nanocarriers requires characterizations of suitable particle size, high drug loading and safety. In this work, we prepared an amphiphilic dendrimer modified PEG-PLA mixed nanoparticles (NPs) by a double emulsion-solvent evaporation (DESE) method. The particle size and drug encapsulation efficacy (EE) were compared to evaluate and optimize the preparation parameters. The mixed NPs had average size ranging from (102±1) nm to (137±5) nm, and the zeta potential turned to positive with incorporation of the amphiphilic dendrimer. The NPs showed different EE of docetaxel (DTX) and paclitaxel (PTX) with higher affinity to more lipophilic PTX. The blank mixed NPs showed little cytotoxicity, and the DTX-loaded NPs could effectively facilitate the antiproliferation activity on PC-3 cells. The NPs could be used as an effective drug delivery system, and its anti-tumor effect is worthy of further study.

Key words: PEG-PLA nanoparticles, Docetaxel, Paclitaxel, Double emulsion-solvent evaporation method, Amphiphilic dendrimer

CLC Number:

R944

Supporting:

Xin Li, Ning Pang, Ji Li, Xianrong Qi. Characterization of amphiphilic dendrimer modified PEG-PLA nanoparticles prepared by a double emulsion-solvent evaporation method[J]. Journal of Chinese Pharmaceutical Sciences, 2017, 26(7): 521-527.

References

[1] Li, Y.; Wang, J.; Wientjes, M.G.; Au, J.L. Adv. Drug Deliv. Rev. 2012, 64, 29-39.

[2] Yang, Z.Z.; Li, J.Q.; Wang, Z.Z.; Dong, D.W.; Qi, X.R. Biomaterials. 2014, 35, 5226-5239.

[3] Lee, W.C.; Li, Y.C.; Chu, I.M. Macromol. Biosci. 2006, 6, 846-854.

[4] Olivier, J.C.; Huertas, R.; Lee, H.J.; Calon, F.; Pardridge, W.M. Pharm. Res. 2002, 19, 1137-1143.

[5] Vila, A.; Sanchez, A.; Evora, C.; Soriano, I.; Jato, J.L.V.; Alonso, M.J. J. Aerosol. Med. 2004, 17, 174-185.

[6] Ishihara, T.; Goto, M.; Kanazawa, H.; Higaki, M.; Mizushima, Y. J. Pharm. Sci. 2009, 98, 2357-2363.

[7] Li, Y.; Qi, X.R.; Maitani, Y.; Nagai, T. Nanotechnology. 2009, 20, 055106.

[8] Feng, L.; Qi, X.R.; Zhou, X.J.; Maitani, Y.; Wang, S.C.; Jiang, Y.; Nagai, T. J. Controlled. Release. 2006, 112, 35-42.

[9] Hadinoto, K.; Sundaresan, A.; Cheow, W.S. Eur. J. Pharma. Biopharma. 2013, 85, 427-443.

[10] Yang, X.Z.; Dou, S.; Sun, T.M.; Mao, C.Q.; Wang, H.X.; Wang, J. J. Controlled. Release. 2011, 156, 203-211.

[11] Colombo, S.; Cun, D.; Remaut, K.; Bunker, M.; Zhang, J.; Martin-Bertelsen, B.; Yaghmur, A.; Braeckmans, K.; Nielsen, H.M.; Foged, C. J. Controlled. Release. 2015, 201, 22-31.

[12] Thevenot, J.; Troutier, A.L.; David, L.; Delair, T.; Ladavière, C. Biomacromolecules. 2007, 8, 3651-3660.

[13] Fenart, L.; Casanova, A.; Dehouck, B.; Duhem, C.; Slupek, S.; Cecchelli, R.; Betbeder, D. J. Pharma. Exper. Ther. 1999, 291, 1017-1022.

[14] Cheow, W.S.; Hadinoto, K. Colloids and Surfaces B: Biointerfaces. 2011, 85, 214-220.

[15] Shi, J.; Xu, Y.; Xu, X.; Zhu, X.; Pridgen, E.; Wu, J.; Votruba, A.R.; Swami, A.; Zetter, B.R.; Farokhzad, O.C. Nanomedicine. 2014, 10, 897-900.

[16] Khan, O.F.; Zaia, E.W.; Yin, H.; Bogorad, R.L.; Pelet, J.M.; Webber, M.J.; Zhuang, I.; Dahlman, J.E.; Langer, R.; Anderson, D.G. Angew. Chem. Int. Ed. Engl. 2014, 53, 14397-14401.

[17] Hu, K.; Xie, Y.; Lu, W. Fudan Univ. J. Med. Sci. 2007, 6, 800-805, 820.

[18] Li, H.J.; Du, J.Z.; Du, X.J.; Xu, C.F.; Sun, C.Y.; Wang, H.X.; Cao, Z.T.; Yang, X.Z.; Zhu, Y.H.; Nie, S.; Wang, J. Proc. Natl. Acad. Sci. U.S.A. 2016, 113, 4164-4169.

[19] Li, P.; Li, X.; Hui, H.; Zhang, Y.; Wang, F.; Liu, Y. Chin. J. New Drugs. 2009, 3, 262-266, 271.

Characterization of amphiphilic dendrimer modified PEG-PLA nanoparticles prepared by a double emulsion-solvent evaporation method

RichHTML

PDF (PC)

Knowledge

Abstract

Cite this article

share this article

References

Related Articles 15

Recommended Articles

Metrics

Comments

[1]	Ciyan Peng, Jing Chen, Sini Li, Jianhe Li, Liubao Peng. Evidence-based pharmacoeconomic evaluation of palbociclib in combination with letrozole versus docetaxel in combination with epirubicin in the first-line treatment of advanced breast cancer with epirubicin [J]. Journal of Chinese Pharmaceutical Sciences, 2023, 32(3): 214-222.
[2]	Shen Lin, Xin Rao, Yiyuan Li, Xiuhua Weng, Changlian Wang. Cost-effectiveness analysis of second-line chemotherapy strategies for patients with advanced non-squamous non-small cell lung cancer [J]. Journal of Chinese Pharmaceutical Sciences, 2020, 29(8): 542-553.
[3]	Yusheng Pei, Tong Cai, Guolai Zhang, Chen Chen, Hua Gao. Detection of bacterial endotoxin in paclitaxel liposome [J]. Journal of Chinese Pharmaceutical Sciences, 2018, 27(6): 436-441.
[4]	Xiaoyou Qu, Yang Zou, Yao Jin, Yuanhang Zhou, Ziqi Wang, Chuyu He, Yunqiang Deng, Xinru Li, Yanxia Zhou, Yan Liu. Preparation and in vitro characterization of paclitaxel-loaded pH-responsive polymeric micelles based on poly(2-ethyl-2-oxazoline)-vitamin E succinate [J]. Journal of Chinese Pharmaceutical Sciences, 2017, 26(8): 582-588.
[5]	Weina Yu, Youyi Xiong, Zhuo Chen, Fang Wang. Alpha-1-acid glycoprotein as potential predictive biomarker of docetaxel adverse effects in breast cancer patients [J]. Journal of Chinese Pharmaceutical Sciences, 2017, 26(12): 895-899.
[6]	Daiying Zhou, Li Ding, Xi Wang, Juan Ma, Wolin Huang, Susan Goodin, Xi Zheng. Synergistic effects of a curcumin analogue and docetaxel on growth inhibition of human prostate cancer cells [J]. Journal of Chinese Pharmaceutical Sciences, 2017, 26(11): 827-833.
[7]	Wei Ren, Shuang Zhang, Ting Zhong, Dan Huang, Xin Yao, Yang Guo, Xiaochuan Duan, Yifan Yin, Shushi Zhang, Xuan Zhang. The preparation and characteristics of sterically stabilized liposomes containing paclitaxel and super-paramagnetic iron oxide nanoparticles [J]. Journal of Chinese Pharmaceutical Sciences, 2016, 25(8): 570-575.
[8]	Fang Wang, Zhuo Chen, Lin Li, Mingzhi Zhu, Youyi Xiong, Yuanting Gu. Pharmacokinetically determined docetaxel exposure as a predictor of hematologic toxicity in Chinese patients with early stage breast cancer [J]. Journal of Chinese Pharmaceutical Sciences, 2016, 25(7): 512-516.
[9]	Jing Sun, Wenbing Dai, Zhe Liang, Zhaoyang Wang, Changsheng Huang, Bing He, Hua Zhang, Xueqing Wang, Qiang Zhang. Advances in the formulation and delivery technology of paclitaxel for injection [J]. Journal of Chinese Pharmaceutical Sciences, 2015, 24(8): 487-500.
[10]	Wenjie Hou, Hua Zheng, Jiancheng Wang. Vapreotide-modified nanomicelle as a targeted nanocarrier for delivering paclitaxel to the tumors with overexpression of somatostatin receptors [J]. Journal of Chinese Pharmaceutical Sciences, 2015, 24(8): 501-513.
[11]	Yu Sun, Xinming Zhang, Lin Tang. Preparation, optimization and in vitro evaluation of core-shell paclitaxel-loaded nanoparticles composed of MPEG-PLA and PLA [J]. Journal of Chinese Pharmaceutical Sciences, 2015, 24(2): 104-110.
[12]	Tingting Meng, Jingquan Li, Xianrong Qi. Preparation and evaluation of lipid-matrix nanocarrier co-delivery gene and sensibilizer to elevate docetaxel antitumor [J]. Journal of Chinese Pharmaceutical Sciences, 2014, 23(3): 145-152.
[13]	Jingquan Li, Zhenzhen Yang, Tingting Meng, Xianrong Qi . The use of cationic liposomes to co-deliver docetaxel and siRNA for targeted therapy of hepatocellular carcinoma [J]. Journal of Chinese Pharmaceutical Sciences, 2014, 23(10): 667-673.
[14]	Zhanzhang Wang, Zhenzhen Yang, Xianrong Qi^*. Hematological and pathological toxicity of anti-HER2/neu peptide mimetic modified paclitaxel bovine serum albumin nanoparticles [J]. , 2013, 22(5): 441-448.
[15]	Junchao Shao, Haixia Lin^*, Yongmei Cui, Shaoman Yin, Erwin G Van Meir, Jiachen Huang. Design, synthesis and evaluation of the cytotoxicity of a N-mustard and paclitaxel conjugate prodrug [J]. , 2013, 22(2): 137-143.